Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Risedronate 5 mg/day vs placebo

Hip Fracture · postmenopausal women at lower risk of fractures1

1 finding from 1 review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
Low

Risedronate 5 mg/day vs placebo

Hip Fracture · pPostmenopausal women at higher risk of fractures1

Risedronate 5 mg/day may leads to lower hip fractures compared with placebo (low certainty).

1 finding from 1 review

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women 2022 · Cochrane Headline outcomes only
RR 0.73 [0.56, 0.94]
Studies not reported
Low